De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Adaptimmune Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Adaptimmune Therapeutics heeft een totaal eigen vermogen van $96.3M en een totale schuld van $25.0M, wat de schuld-eigenvermogensverhouding op 25.9% brengt. De totale activa en totale passiva bedragen respectievelijk $321.7M en $225.4M.
Belangrijke informatie
25.9%
Verhouding schuld/eigen vermogen
US$24.95m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$214.79m |
| Aandelen | US$96.27m |
| Totaal verplichtingen | US$225.43m |
| Totaal activa | US$321.70m |
Recente financiële gezondheidsupdates
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Recent updates
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Adaptimmune slips as Barclays initiates with an underweight rating
May 28Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $253.8M ) ADAP } overtreffen de korte termijn passiva ( $82.1M ).
Langlopende schulden: De kortetermijnactiva ADAP ( $253.8M ) overtreffen de langetermijnschulden ( $143.4M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: ADAP heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van ADAP is de afgelopen 5 jaar gestegen van 0% naar 25.9%.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: ADAP heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.
Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of ADAP voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.